RSS Feed
Search Ask-Cato.com
Tags
adverse events biologics biosimilar biotech cancer Cato BioVentures Cato Research CDER clinical investigator clinical research clinical trials CMC conference CROs DIA drug development eCTD efficacy FDA funding GlobalSubmit guidance Health Canada IND in vitro diagnostics labeling manufacturing marketing application medical devices NDA NIH nonclinical research oncology Phase 1 Phase 2 postmarketing protocol regulatory affairs safety statistical analysis toxicology transparency venture capital warning letters webinarCategories
- Clinical Trials (52)
- Conferences and Meetings (34)
- eCTD (26)
- FDA (71)
- Guest Posts (5)
- Health Canada (6)
- Industry News (56)
- Project Management (1)
- Publications (7)
- Regulatory Strategy (36)
- Social Media (6)
- Statistics (9)
- Uncategorized (1)
- Venture Capital (10)
- Webinars (24)
Tag Archives: adverse events
Free Educational Webinar – New Rules in FDA Safety Reporting: Are You Prepared?
UPDATE: The slides from the webinar are now available for download here. Please join us on Wednesday, 15 June (10:00 AM EDT) as we focus on the FDA’s new rule, “Investigational New Drug Safety Reporting Requirements for Human Drug and … Continue reading
Posted in Clinical Trials, Webinars
Tagged adverse events, bioavailability, bioequivalence, clinical trials, FDA, guidance, IND, pharmacovigilance, safety, webinar
Comments Off
FDA Enforcement of New IND and BA/BE Safety Reporting Requirements
FDA announced at the end of March 2011 that the new IND and bioavailability/bioequivalence (BA/BE) study reporting requirements (final rule published September 29, 2010), originally effective on March 28, 2011, will not be enforced until September 28, 2011. FDA’s intent … Continue reading
Posted in Clinical Trials, FDA, Industry News
Tagged 21 CFR, adverse drug reactions, adverse events, bioavailability, bioequivalence, clinical investigator, FDA, IND, safety
1 Comment
